One Year Later, Families Await Answers on Suspended Duchenne Drug
Families of children with Duchenne Muscular Dystrophy (DMD) are facing a year-long delay in accessing the Elevidys medication, with no clear answers from Brazil's National Health Surveillance Agency (Anvisa). The drug, which can slow muscle degeneration in boys up to age 8, was suspended on July 24, 2025, following reports of two patient deaths and concerns about liver side effects in the United States. Anvisa cited these international reports as the reason for the suspension, despite the drug having been temporarily approved in Brazil for six months prior. The Jordão family, whose six-year-old son Arthur has DMD, is among those anxiously awaiting a decision. The critical window for administering Elevidys is before a child turns 7 years and 11 months, a deadline that is rapidly approaching for many patients. In June 2026, a parliamentary committee met to press Anvisa and the drug's manufacturer, Roche, for a resolution. Arthur's mother, Natália Jordão, voiced her frustration over the prolonged review process, highlighting the number of children who may have aged out of eligibility during the delay. Anvisa stated it is receiving documents from the laboratory but cannot provide a timeline for the evaluation's conclusion. Roche confirmed it submitted updated safety and efficacy data in June 2026 and maintains confidence in the drug's benefit-risk profile. Pharmaceutical science experts note that rare disease drug evaluations are complex and require thorough data from manufacturers, especially when international safety alerts arise. The ongoing delay underscores the urgent need for a timely regulatory process for life-altering treatments.
The extended suspension of Elevidys by Anvisa, following international safety alerts, highlights a critical tension between regulatory caution and urgent patient needs, particularly for rare pediatric diseases. While Anvisa's mandate includes rigorous safety evaluation, the year-long delay in providing a definitive decision, despite ongoing submissions from the manufacturer, raises questions about the efficiency of Brazil's regulatory processes for innovative therapies. The situation underscores the systemic challenge of balancing the imperative to protect public health from potential risks with the ethical obligation to provide access to potentially life-changing treatments within a narrow therapeutic window. Future regulatory frameworks may need to incorporate more agile review pathways for rare disease drugs, perhaps through enhanced international collaboration and conditional approvals tied to robust post-market surveillance, to mitigate the impact of such prolonged uncertainties on vulnerable patient populations.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.